New Wet AMD Treatments Show Potential in Phase 3 Trials
The American Academy of Ophthalmology reports that new therapeutic classes may soon offer alternatives to regular eye injections.
Updated on Oct. 16, 2026 in Biotech
Live Poll
Do you believe newer medical treatments are successfully reducing the burden of long-term healthcare?
At its recent annual meeting in New Orleans, the American Academy of Ophthalmology reviewed advancements in treating wet age-related macular degeneration (AMD). Experts highlighted the role of diagnostic imaging and emerging clinical trial data for new therapy classes.
Why it matters
Precision diagnostics are critical for ensuring patients receive appropriate long-term care rather than standard anti-VEGF injections. These developments aim to improve therapeutic outcomes and potentially reduce treatment burdens for those with the condition.
Phase 3 results for tyrosine kinase inhibitors demonstrate clinical outcomes comparable to existing anti-VEGF injection standards. These findings provide a potential alternative to the current standard-of-care for wet AMD management.
The players
American Academy of Ophthalmology
The professional medical association representing ophthalmologists globally, focused on clinical standards and research.
Sunir Garg
An ophthalmology specialist focused on diagnostic and treatment advancements for retinal diseases.
The details
Clinicians are increasingly using multimodal imaging to distinguish wet AMD from look-alike conditions before initiating therapy. This suite includes optical coherence tomography (OCT) — a non-invasive scan using light waves to take cross-section pictures of the retina — alongside OCT angiography and fluorescence imaging. Emerging gene therapies are also under study, utilizing subretinal, intravitreal, or suprachoroidal delivery approaches to modify how the eye cells produce therapeutic proteins.
Timeline
The American Academy of Ophthalmology annual meeting occurred in October 2026.
The Tech Race
The ophthalmology field is moving toward reducing treatment frequency for wet AMD patients, who currently face regular injections. These findings mark a shift in the race to diversify treatment options beyond standard anti-VEGF agents.
Patients with wet AMD may eventually see fewer office visits as tyrosine kinase inhibitors and gene therapies progress through clinical milestones. These treatments are not yet available to the public and remain subject to regulatory review and long-term safety validation.
The takeaway
The sector is aggressively targeting a shift from frequent eye injections to more durable, less invasive therapeutic delivery. Watch for updates on Phase 3 clinical outcomes that will confirm if these new inhibitors can maintain efficacy over multi-year periods.
Further reading
For more on the latest research in vision restoration, explore our Biotech section.
Source note: This article includes information reported by Medscape.
Live Poll
Do you believe newer medical treatments are successfully reducing the burden of long-term healthcare?
